




Sociedad Española
de Reumatología -
Colegio Mexicano
de Reumatología

Reumatología Clínica

www.reumatologiaclinica.org



Letter to the Editor

Comment on “Prevalence of hidradenitis suppurativa in patients with axial spondyloarthritis”



Comentario sobre “Prevalencia de hidradenitis suppurativa en pacientes con espondiloartritis axial”

Dear Editor,

We read the article “Prevalence of hidradenitis suppurativa in patients with axial spondyloarthritis” published in *Reumatología Clínica* journal with great interest.¹ The study explored the prevalence of hidradenitis suppurativa (HS) in 265 axial spondyloarthritis (AxSpA) patients with the help of questionnaires and dermatologist confirmation. Of the 148 patients who completed the screening questionnaire, 2.7% had HS, greater than the general population rates.² HS patients exhibited higher smoking rates, elevated disease activity, and shorter AxSpA duration. The results stress the importance of HS screening integration into AxSpA care to strengthen diagnosis and treatment. While their findings are significant and fill a significant gap in the literature by addressing important clinical correlations, several methodical limitations warrant discussion.

Firstly, although the cross-sectional study facilitates finding prevalence and association, it measures the exposure and the outcome but fails to establish a temporal relationship which prevents it from determining causality; whether the exposure led to the outcome or the outcome influenced the exposure.³

Similarly, the study does not mention whether a power analysis was conducted to calculate the sample size, which is crucial to detect the accurate prevalence of HS in AxSpA patients. Without it, the study risks a type II error which might result in the observed prevalence (2.7%) being statistically unreliable.⁴

Moreover, the study required patients to have experienced at least two HS flares in the past six months. However, the use of medications like GLP-1 receptor agonists and metformin in patients with coexisting diabetes and AxSpA reduces HS flare severity.⁵ This leads to the exclusion of a certain portion of patients, causing not only the underestimation of actual HS prevalence in AxSpA patients but also the overstating of associations with severe disease.

Selection bias may have influenced the results due to the exclusion of patients with cognitive impairment, language barriers, and certain comorbidities, overlooking the more vulnerable populations. Inequalities in healthcare access and disease severity amongst different groups also affect the prevalence estimates significantly.⁶ This limitation of the study can be addressed in future studies by adding a more diverse patient population that would enhance both the accuracy and applicability of the findings.

Additionally, underlying conditions such as thyroid disorders and calcium abnormalities, which can contribute to HS develop-

ment, were not accounted for. These factors may have affected the accuracy of the study's prevalence estimates. We believe that the co-occurrence of such diseases should have been investigated a bit before carrying out the study to rule out if the development of HS was due to AxSpA or some other underlying disorder.⁷

Furthermore, we believe that even though the Hurley questionnaire used to estimate the severity of the disease is undoubtedly an inclusive and sensitive scale, it could have benefitted from a few modifications. Adding questions about the development of inflammatory nodules and abscesses formation before it progressed into a sinus may have resulted in a better assessment of HS severity and its progression.⁸ These amendments, in our opinion, could have enhanced the scope of the study and improved its quality.

A critical limitation of the study is the failure to adjust for confounding variables such as disease activity levels (e.g., BASDAI scores) and smoking status, both of which may differ between HS and non-HS groups. Addressing this limitation in future research would help ensure more accurate estimations of the true relationship between HS and AxSpA.

Despite these limitations, the study successfully highlights the prevalence of HS in AxSpA using a cross-sectional approach. However, its single-center design, selection bias, and lack of confounder adjustments restrict its applicability. Enhancing the Hurley questionnaire and implementing methodological refinements in future studies would strengthen the validity of these findings and their relevance to broader clinical practices.

Funding

No funds, grants, or other support was received.

Conflict of interest

The authors have no relevant financial or non-financial interests to disclose.

References

1. Farran Ortega L, Fornons-Servent R, Nolla JM, Juanola Roura X. Prevalence of hidradenitis suppurativa in patients with axial spondyloarthritis. *Reumatol Clin (Engl Ed)*. 2025;21:501808, <http://dx.doi.org/10.1016/j.reumae.2025.501808>.
2. Jfri A, Nassim D, O'Brien E, Gulliver W, Nikolakis G, Zouboulis CC. Prevalence of hidradenitis suppurativa: a systematic review and meta-regression analysis. *JAMA Dermatol*. 2021;157:924–31, <http://dx.doi.org/10.1001/jamadermatol.2021.1677>.
3. Wang X, Cheng Z. Cross-sectional studies: strengths, weaknesses, and recommendations. *Chest*. 2020;158:S65–71, <http://dx.doi.org/10.1016/j.chest.2020.03.012>.
4. Lu N, Han Y, Chen T, Gunzler DD, Xia Y, Lin JY, et al. Power analysis for cross-sectional and longitudinal study designs. *Shanghai Arch Psychiatry*. 2013;25:259–62, <http://dx.doi.org/10.3969/j.issn.1002-0829.2013.04.009>.
5. Patino W, Thomas A, Jain S, Del Rosso JQ, Issa NT. A review of glucagon-like peptide-1 in dermatology. *J Clin Aesthet Dermatol*. 2025;18:42.

<https://doi.org/10.1016/j.reumae.2025.501914>

2173–5743/© 2025 Sociedad Española de Reumatología (SER), Colegio Mexicano de Reumatología (CMR) and Elsevier España, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

6. Murray S, Buller AM. Exclusion on grounds of language ability: a reporting gap in health services research? *J Health Serv Res Policy*. 2007;12:205–8, <http://dx.doi.org/10.1258/135581907782101642>.
7. Phan K, Huo YR, Charlton O, Smith SD. Hidradenitis suppurativa and thyroid disease: systematic review and meta-analysis. *J Cutan Med Surg*. 2020;24:23–7, <http://dx.doi.org/10.1177/1203475419874411>.
8. Rondags A, Volkering RJ, Turcan I, Zuidema YS, Janse IC, Horvath B. The refined Hurley patient questionnaire: an accurate self-assessment instrument for deriving the correct refined Hurley stage in hidradenitis suppurativa. *Acta Derm Venereol*. 2019;99:703–4, <http://dx.doi.org/10.2340/00015555-3126>.

^b Dow University of Health Sciences, Karachi, Pakistan

^c Ayub Medical College, Abbottabad, Pakistan

^d Peoples University of Medical and Health Sciences for Women, Nawabshah, Pakistan

* Corresponding author.

E-mail address: Sarahaijaz13@gmail.com (S. Aijaz).

Sarah Aijaz^{a,*}, Raveen Muzaffer^b, Muhammad Zarrar^c,
Zauha Fawad Memon^d

^a United Medical and Dental College, Karachi, Pakistan